Thank you Ryan Cross at Endpoints News for covering Mammoth and our progress to advance our lead program, MB-111 to clinical trials next year. #CRISPR #UltracompactCRISPR https://lnkd.in/ge9KjjSN
Mammoth Biosciences
Biotechnology Research
Brisbane, California 54,707 followers
Improving lives by reading and writing the code of life.
About us
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
- Website
-
http://www.mammoth.bio
External link for Mammoth Biosciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
1000 Marina Blvd
Suite 600
Brisbane, California 94005, US
Employees at Mammoth Biosciences
Updates
-
Mammoth is at #ESGCT in Seville, Spain! Associate Director Sean Chen will present Mammoth’s latest NHP data supporting our lead program, MB-111. https://lnkd.in/g5r2PdA6 #CRISPR #UltracompactCRISPR
-
-
"Mammoth does fundamental innovation on the CRISPR side, and the advances that Regeneron has made on the delivery side bring the best of both worlds." Mammoth Biosciences Co-founder and CTO, Janice Chen, recently joined Leah Sabin, Executive Director, Genetic Medicines at Regeneron on The Nucleus podcast to discuss CRISPR 2.0. From ultracompact editing systems to the complexities of in vivo delivery, this episode is a must-listen for anyone interested in the history as well as the future of precision medicine. ▶️ Listen to the full episode here: https://lnkd.in/gxnc8YW4 #CRISPR #UltracompactCRISPR #TheNucleus #FutureofBiotech
-
-
Our Co-Founder and CEO, Trevor Martin will be in Boston next week for #WMIF2025. Looking forward to this session moderated by Ben Kleinstiver, where they will discuss current advances and challenges of gene editing, alongside fellow panelists Steve Favaloro, Laura Sepp-Lorenzino, Ph.D., and David R. Liu. #CRISPR
-
-
Mammoth Biosciences reposted this
Excited to partner with Frederic D. Sweeney and the VedaBio team to enable their next-generation diagnostics products with Mammoth Biosciences's CRISPR detection technologies! We are thrilled to see both teams' innovations unlock new solutions for fast, accurate and accessible diagnostics. This non-exclusive license agreement to Mammoth Biosciences's select CRISPR detection technologies is another step towards our vision to improve lives with transformative CRISPR products across multiple applications. We look forward to accelerating the path for developers to bring the full promise of CRISPR diagnostics to market.
Exciting news from VedaBio! We’re proud to announce a new agreement with Mammoth Biosciences to expand our CRISPR-based molecular detection platform. Through this collaboration, VedaBio gains access to foundational CRISPR technologies, strengthening our mission to deliver amplification-free, purpose-built diagnostics for real-world clinical needs. This milestone brings us closer to creating faster, more accurate, and cost-effective diagnostic solutions that can thrive in decentralized healthcare settings like urgent care and outpatient clinics. Together with Mammoth’s groundbreaking CRISPR innovations, we are building the future of molecular detection designed for speed, accuracy, and accessibility. https://lnkd.in/gZQJwP-C
-
We're #hiring a new Scientist II/Senior Scientist I, LNP Process Development in Brisbane, California. Apply today or share this post with your network.
-
We're #hiring a new Scientist II/Senior Scientist I, LNP Process Development in Brisbane, California. Apply today or share this post with your network.
-
🏅At Mammoth Biosciences our mission is simple: to broaden the range of diseases that can be treated and dramatically increase the number of patients who could benefit from genetic medicines. We are proud to announce that Mammoth Biosciences has been nominated for the 2025 Prix Galien USA Award in the Best Startup category! This honor recognizes our breakthrough work in extrahepatic ultracompact #CRISPR systems such as NanoCas, our first clinical developmental candidate, MB-111, and the relentless passion and dedication of our entire team. A huge thank you to The Galien Foundation for this recognition, and congratulations to our fellow nominees. We look forward to celebrating together at the award ceremony in New York City on October 30!
-
-
We're #hiring a new Scientist II/Senior Scientist I, LNP Process Development in Brisbane, California. Apply today or share this post with your network.
-
We're #hiring a new Scientist II/Senior Scientist I, LNP Process Development in Brisbane, California. Apply today or share this post with your network.